Standard usage and recommended dosage of Erlotinib/Tarceva

Erlotinib (Erlotinib) is an oral small molecule targeted drug that blocks tumor cell proliferation signals mainly by inhibiting EGFR tyrosine kinase activity. Correct usage and dosage are critical to ensure efficacy and reduce the risk of side effects.

In the treatment of non-small cell lung cancer ( NSCLC), the recommended dose is 150 mg once daily. It should be noted that patients must take the drug on an empty stomach, that is, at least one hour before or two hours after eating, to ensure the stability of drug absorption rate and blood concentration. Treatment is usually continued until disease progression or intolerable toxicity occurs. It is recommended to conduct EGFR mutation testing before treatment. If there is EGFR exon 19 deletion or exon 21 (L858R) mutation in tumor tissue or plasma specimens, the patient will benefit more from erlotinib treatment. If no mutations are found in plasma testing, further clinical testing of tumor tissue is often recommended to avoid treatment bias due to false negatives.

In the treatment of pancreatic cancer, the combination of erlotinib and gemcitabine is a common regimen. The recommended dose is 100mg, once a day, also on an empty stomach. Combination with gemcitabine can prolong the survival time of some patients with advanced pancreatic cancer to a certain extent, but its efficacy is relatively limited, so the overall condition of the patient usually needs to be considered in its application.

During treatment, doctors will adjust the dosage based on the patient's tolerance and adverse reactions. Common side effects include rash, diarrhea, anorexia, and fatigue, and most can be relieved with supportive treatment or necessary dose adjustments. Serious adverse events, such as interstitial lung disease or severe liver injury, require immediate discontinuation and symptomatic treatment.

In addition, patients need to avoid taking strongCYP3A4 inhibitors or inducers at the same time to avoid affecting the metabolism level of erlotinib in the body. In addition, smoking should be avoided because smoking will significantly reduce the blood concentration of the drug, thereby affecting its efficacy. During the period of taking the medicine, it is recommended that patients be followed up regularly and undergo liver and kidney function and tumor imaging examinations in order to timely evaluate the treatment effect and safety.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib